A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Dapagliflozin/saxagliptin (Primary) ; Dapagliflozin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 02 Feb 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Aug 2014 New trial record